Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.46 |
| ▸ | FNTB | P49356 | 9/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434794 | 0.84 | FNTA (0.47) | FNTAFNTBPGGT1BOPRM1OPRK1 | |
| SCHEMBL4425431 | 0.80 | FNTA (0.60) | FNTAFNTBPGGT1B | |
| SCHEMBL4428148 | 0.78 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL4426318 | 0.77 | FNTA (0.49) | FNTAFNTBPGGT1BGSK3BUCHL1 | |
| SCHEMBL4426275 | 0.75 | FNTA (0.55) | FNTAFNTBPGGT1BGSK3BKDM4E | |
| SCHEMBL4423462 | 0.75 | FNTA (0.57) | FNTAFNTBPGGT1B | |
| SCHEMBL29445867 | 0.74 | FNTA (0.53) | FNTAFNTBPGGT1BGSK3BKDM4E | |
| Water SCHEMBL7207857 | 0.74 | FNTA (0.67) | FNTAFNTBPGGT1B | |
| SCHEMBL7203407 | 0.74 | FNTA (0.55) | FNTAFNTBPGGT1BOPRM1OPRK1 | |
| SCHEMBL5022569 | 0.70 | FNTA (0.47) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458720-B1 | 1,8-ANNELATED QUINOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED TRIAZOLES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-18 | — | — | EP | disclosed |
| US-7408063-B2 | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-05 | — | — | US | disclosed |
| US-20050176702-A1 | 1,8-Annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176702-A1 | 1,8-Annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors | FNTA, FNTB, ACAT2 | FNTA 1/4885FNTB 2/4885PGGT1B 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.